Elsevier, European Journal of Cancer - Supplement, 14(6), p. 46-51, 2008
DOI: 10.1016/j.ejcsup.2008.06.013
Full text: Download
Objective: To assess the burden of renal cell carcinoma (RCC) in epidemiologic and economic terms. Methods: Retrospective, naturalistic longitudinal study on the occurrence, outcomes and cost of RCC using an administrative database. We selected residents of Friuli-Venezia-Giulia (FVG), a North-eastern Region of Italy, who had a RCC first hospital admission during the period 2000-2004, and we followed them up until: 30th June 2005, death or transfers. Direct medical costs were quantified in the perspective of FVG Regional Health Service. Results: We enrolled 1358 patients (63% male), the 18.8% presenting a metastatic-stage, leading to a crude incidence of 23/100.000 person-years. During the follow-up, 76% of the metastatic patients and 21% of the non-metastatic patients died. Total health care costs per-patient over the maximum of follow-up were 16,090(sic) for the localised stage group and 17,656(sic) in the metastatic-stage group. Discussion: RCC imposes a significant epidemiologic and economic burden to the health-care-system and the society.